rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Michelle Gilson

Director

Company insider

Files Form 4 as: Director, Rani Therapeutics Holdings; Chief Financial Officer, Arcellx.

Every Form 4 they filed

In numbers

Trades disclosed
129
Buys
0
Sells
22
Bought
$0
Sold
$15.6M
Companies
2
Companies where not an officer
1
First trade
23 May 2022
Last trade
3 Aug 2026
Last filed
4 Aug 2026

Companies traded

Where they are an officer
ArcellxOfficer · Biotechnology · last 28 Apr 20260 buys · 22 sells
Everywhere else they filed: board seats, 10% stakes, other companies
RANI Rani Therapeutics HoldingsDirector · Biotechnology · last 3 Aug 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
40Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
3 Aug 2026filed 4 Aug 2026RANI Rani Therapeutics Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—247,200 at $0.00filing
3 Aug 2026filed 4 Aug 2026RANI Rani Therapeutics Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—247,200 at $0.00filing
28 Apr 2026filed 28 Apr 2026ArcellxBiotechnologySEC FORM 4 Code U—67,048filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code A—59,028filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—59,028filing
28 Apr 2026filed 28 Apr 2026ArcellxBiotechnologySEC FORM 4 Code U—5,000filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—40,205filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—40,205filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—32,500filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—70,796filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—94,596filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—20,496filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—61,590filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—88,542filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code A—59,028filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—59,028filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—32,500filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—70,796filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—94,596filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—20,496filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care3
Not placed22

Buys in green, sells in red, by the company’s sector.

Related people

Andrew H. GalliganDirector · Director at Arcellx, filing Form 4 there in the last year
David Charles LubnerDirector · Director at Arcellx, filing Form 4 there in the last year
Jill CarrollDirector · Director at Arcellx, filing Form 4 there in the last year
Rami ElghandourDirector and Officer · Insider at Arcellx, filing Form 4 there in the last year
Ali BehbahaniDirector · Director at Arcellx, filing Form 4 there in the last year